Protective Effects of Dietary Supplementation with a Combination of Nutrients in a Transgenic Mouse Model of Alzheimer’s Disease

Shengyuan Wang1, Yu C1, Chao Wang2, Wei Xie3, Lan Ma3, Jinfeng Zhu3, Yan Zhang3, Rui Dang3, Decai Wang3, Yonghui Wu4*, Qunhong Wu1*

1 Department of Social Medicine, Public Health College, Harbin Medical University, Harbin, China, 2 Department of Nutrition, YanZhou people’s hospital, YanZhou, China, 3 Department of Nutrition and Food Hygiene, Public Health College, Harbin Medical University, Harbin, China, 4 Department of Occupational Health, Public Health College, Harbin Medical University, Harbin, China

☯ These authors contributed equally to this work.
* wuyonghui777@163.com (YHW); wuqunhonghyd@163.com (QHW)

Abstract

Objective

This study investigated the effects of intervention with a combination of nutrients in the amyloid precursor protein-presenilin (APP-PSN) C57BL/6J double transgenic mouse model of Alzheimer’s disease (AD).

Methods

A total of 72 2-month-old APP-PSN mice were randomly assigned to three groups. The model group (MG) was fed regular, unsupplemented chow, while the low- and high-dose treatment groups (LG and HG, respectively) were given a combination of nutrients that included phosphatidylserine, blueberry extracts, docosahexaenoic acid, and eicosapentaenoic acid as part of their diet. An additional 24 wild-type littermates that were fed unsupplemented chow served as the negative control group (NG). After 3 and 7 months of treatment, the cognitive performance was assessed with the Morris water maze and the shuttle box escape/avoidance task, and the biochemical parameters and oxidative stress were evaluated in both the blood and brain.

Results

An improvement in antioxidant capacity was observed in the treatment groups relative to the MG at 3 months, while superior behavioral test results were observed in the mice of the HG and NG groups. In the MG, pycnosis was detected in neuronal nuclei, and a loss of neurons was observed in the cerebral cortex and the hippocampus. At 7 months, the β-amyloid1–42 peptide accumulation was significantly elevated in the MG but was markedly lower...
in the mice fed the nutrient combination. The antioxidant capacity and behavioral test scores were also higher in these mice.

Conclusions

Early intervention with a combination of nutrients should be considered as a strategy for preventing cognitive decline and other symptoms associated with AD.

Introduction

Alzheimer’s disease (AD) is increasingly becoming a global public health burden with an estimated prevalence of over 100 million individuals by 2050 [1] because of the longer lifespan. As the most common form of dementia, AD is a progressive neurodegenerative disorder that is characterized by the presence of extracellular neuritic plaques and intracellular neurofibrillary tangles. The clinical symptoms of AD include memory loss, impaired cognitive function, a decline in the ability to perform day-to-day activities, and changes in personality and behavior [2, 3]. Although the precise etiology of AD is not fully known, it likely involves several processes, such as oxidative stress, abnormal processing of β-amyloid, epigenetic mechanisms, low levels of acetylcholine (ACh), mitochondrial dysfunction, and membrane deterioration, among others [4–9].

At present, there are not any effective therapeutic agents for treating AD [10, 11]. Furthermore, there are significant barriers to treatment, ranging from the physiological (the side effects of currently available drugs) to the economical (high fees for medical services and nursing care) factors [12]. Thus, new approaches for delaying the onset and progression of AD are urgently needed. With this goal in mind, early intervention with a combination of nutrients shows promise. More specifically, studies have reported that a variety of nutrients are beneficial for AD prevention, including B vitamins [13], lutein [14], lecithin [15], and omega-3 polyunsaturated fatty acids [16, 17], such as docosahexaenoic acid (DHA) and eicoapentaenoic acid (EPA). For instance, DHA can reduce Aβ accumulation as well as participates in neural repair and protection [16], and antioxidants reduce ROS-induced neuronal damage and stabilize membranes [18]. Furthermore, PS can improve cognitive function due to its numerous functions, including the regulation of receptors, enzymes, ion channels, and signaling molecules [19, 20]. Recently, the nutritional interventions study in humans suggested that supplementation with the macular carotenoids has the benefits on the patients with AD because of the improvements of visual function [21], while oral supplementation with long-chain polyunsaturated fatty acids or lutein/zeaxanthin had no statistically significant effect on cognitive function [22].

In addition, some nutrients, such as selenium, zinc, vitamin E, and blueberry extract, may provide a wide range of antioxidant benefits in AD [23, 24]. Subash et al. reported that the chronic dietary supplementation of date palm fruits showed possible beneficial effects concomitant with oxidative stress reduction, increased antioxidant enzymes, improved memory, learning and reduced beta amyloid in AD transgenic mice model [25, 26]. In addition, as part of the cell membrane, PS, EPA, and DHA directly modulate the activities of intracellular signaling and metabolic pathways that have a broad range of downstream physiological effects [27]. However, single-nutrient and -target study designs are somewhat limited [28], and the importance of considering an assortment of nutrients rather than just individual components is gaining increasing recognition in nutritional intervention studies [29]. The hypothesis of this design to mechanism of action is shown in Fig 1.
In this study, the aim is to investigate the effect of dietary supplementation with phosphatidylserine (PS), blueberry extracts, DHA, and EPA on the cognitive function and oxidative stress in an amyloid precursor protein-presenilin (APP-PSN) double transgenic mice. The results demonstrated that the AD symptoms of animals receiving dietary supplementation were significantly diminished and oxidative stress were improved, which suggested that the incorporation of these ingredients into a diet could lead to protect against the cognitive deficits and cellular damage in the onset and the development of AD.

Materials and Methods

Materials

The Morris water maze, SDT-8 platform, and STT-100 shuttle box device were provided by the Cheng Du Taimeng Technology Co., Ltd. (Sichuan, China). The ingredients for the regular chow (corn starch, casein, maltodextrin, sucrose, powdered cellulose, and L-cysteine) were obtained from the Star Biological Technology Co., Ltd. (Beijing, China). The ingredients for the treatment (selenium; zinc; vitamins E, B12, and B6; folic acid; lutein; PS; DHA; and EPA) were purchased from the Beijing Boxing Biological Technology Co., Ltd. (Beijing, China). Blueberry extracts (≥ 50% procyanidine) were from the Daxinganling Lingonberry Organic Foodstuffs Co., Ltd. (Shanghai, China), and the anti-β-amyloid (Aβ)_{1-42} antibody (ab10148) was obtained from Abcam (Hong Kong).

Animals

All experiments were performed in strict accordance with the recommendations found in the Guide for the Care and Use of Laboratory Animals of the Institute of Zoology. Furthermore, the study protocol was approved by the Medical Ethics Committee of Harbin Medical University. Amyloid precursor protein-presenilin (APP-PSN) C57BL/6J double transgenic mice (n = 72) and their wild-type littermates (n = 24) were purchased from the Model Animal

Fig 1. The possible mechanisms of action of compound nutrients. Ach: acetylcholine; cAMP: Cyclic adenosine monophosphate; APP: amyloid precursor protein-presenilin; Aβ: anti-β-amyloid; GSH-PX: glutathione peroxidase; SOD: superoxide dismutase; TChE: total cholinesterase.
Resource Platform of Nanjing University (license number SCXK [Su] 2010–0001). The transgenic mice express a chimeric mouse/human APP (Mo/HuAPP695swe) and mutant human PS (PS1-dE9) in CNS neurons under the control of independent mouse prion protein promoter elements associated with early onset AD [30, 31], and they develop Aβ deposits in the brain by 6 to 7 months of age [32]. Genotypes were confirmed by PCR genotyping using genomic DNA extracted from tail tissue samples, and the process was performed by the Model Animal Resource Platform of Nanjing University.

Diet
The animals (2 months old) were acclimatized for 1 week, and then, the transgenic mice were randomly divided into three groups of 24 animals each, with equal numbers of males and females: the model group (MG) that was fed normal chow and the low and high treatment groups (LG and HG, respectively). Wild-type mice were fed normal chow and served as the negative control group (NG). The animals were maintained in a pathogen-free environment on a 12:12-h light/dark cycle with free access to food and water. The composition of ingredients in the nutrient combination diet is shown in Table 1 [33]. The high dose corresponded to the highest recommended intake for humans, while the low dose was half that of the high dose. The feed was prepared as granules, and both the food intake and body weight were recorded weekly for each animal.

Morris water maze
At 3 and 7 months after the start of the treatment regimen, 12 mice were randomly selected from each of the four groups for behavioral testing. Spatial learning and memory were assessed with the Morris water maze [34, 35]. The test consisted of 5 days of place learning and 1 day of space exploration in a black circular pool (diameter × height, 120 × 40 cm), with antholeucin (Harbin Sunshine Food Additive Co., Ltd., Harbin, China) added to the water (20°C ± 1°C) to render it opaque and the platform invisible. The pool was divided into four quadrants (I–IV) and was surrounded by black curtains. Landmarks placed inside the enclosure were used by the animal to locate the platform (7 cm diameter and 1.5 cm below the water surface) that was placed in quadrant III. Before the experiment, the animals were placed in a pool without the platform for 60 s to allow adaptation, and then, they were gently released from a starting point.

| Component          | MG/NG  | LG      | HG      |
|--------------------|--------|---------|---------|
| zinc carbonate     | 57.75 mg/kg | 115.50 mg/kg | 231 mg/kg |
| sodium selenate    | 0.35 mg/kg  | 0.70 mg/kg  | 1.4 mg/kg |
| 50% VE             | 150.00 mg/kg | 2.25 g/kg  | 4.5 g/kg |
| VB6                | 7.00 mg/kg  | 35.00 mg/kg | 70 mg/kg |
| 0.1% VB12          | 25.00 mg/kg | 125.00 mg/kg | 250 mg/kg |
| folic acid         | 2.00 mg/kg  | 2.50 mg/kg  | 5 mg/kg |
| lutein             | ———        | 1.00 mg/kg.bw | 2.00 mg/kg.bw |
| DHA+EPA (5:1)      | ———        | 100.00 mg/kg.bw | 200.00 mg/kg.bw |
| phosphatidylserine | ———        | 20.00 mg/kg.bw | 40.00 mg/kg.bw |
| blueberry extracts | ———        | 50.00 mg/kg.bw | 100.00 mg/kg.bw |

**Note:** (1) LG-low intervention group, HG- high intervention group, MG- model group, NG- negative control group. (2) Other components of the feed formula were based on AIN-93M. (3) The purity of each constituent was based on AIN-93M.

doi:10.1371/journal.pone.0143135.t001
in one of the quadrants. Mice that found the platform within 60 s were permitted to stay on the platform for 10 s; the others were placed on the platform for 10 s. The place learning task consisted of four trial sessions per day for 5 days, and on the sixth day, the platform was removed from the maze, and the mice performed a 60-s probe trial test. A computerized tracking system was used to record and analyze the mice's movement.

**Shutter box escape/avoidance task**

The experiment was carried out in shutter boxes consisting of two equal-sized compartments (25 × 25 × 28 cm) connected by an opening (8 × 10 cm) [36]. Diffused illumination was provided by a fluorescent bulb that was placed in the ceiling of the boxes. Mice were acclimatized inside the shutter box shock area for 5 min and were then given the conditioned stimulus (lights) for 20 s, followed by the unconditioned stimulus (a 24-V, 50 Hz electric shock though the grid floor) for 10 s. One round of the task was complete when the animal crossed to the other compartment, with crossing during the conditioned or unconditioned stimulation being considered as avoidance and escape responses, respectively. The training consisted of a single 40-trial session over the course of 1 day, with the test repeated after 24 h. A camera was placed in the center of the ceiling in each box to record and analyze the mice's movement.

**Biochemical parameters**

A total of 12 mice in each group were used for the behavioral studies after 3 and 7 months of treatment. The mice fasted for 12 h; then, they were anesthetized with 10% chloral hydrate, and a blood sample was drawn from the eyeball for biochemical analyses. The brain was removed from six of the animals in each group, frozen in liquid nitrogen, cut into two halves by midsagittal dissection, and then kept at −80°C. The left half was ground using a mortar and pestle on dry ice and afterwards was homogenized in normal saline (1:9 weight in g:volume in ml). The homogenate was centrifuged at 4°C and 2500 × g for 15 min, and the supernatant was used to measure the levels of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), malondialdehyde (MDA), total cholinesterase (TChE), and total protein by spectrophotometry (except for MDA) (8500 UV-VIS; Techcomp, Ltd., Shanghai, China) using the appropriate kit (Nanjing Jiancheng Biochemistry Co., Nanjing, China) according to the manufacturer’s protocols. The only deviation was a dilution of the supernatant by 10-fold with normal saline for the SOD and protein measurements. The blood was centrifuged at 20°C and 3000 × g for 15 min. The serum was stored at 4°C for a maximum of 3 days before its use in assays for MDA, SOD, acetylcholine (ACh), and TChE.

MDA was assayed with the thiobarbituric acid heating method. To measure the SOD activity, the method employing the reaction of superoxide radicals with hydroxylamine to form a red formazan dye at 550 nm was used. The SOD activity was then measured as the degree of inhibition of this reaction, and the results were given as U/mg or U/ml in the brain and serum, respectively. The GSH-Px activity was measured by the consumption of reduced glutathione in the enzymatic reaction with 5,5′-dithiobis(2-nitrobenzoic acid), which resulted in a yellow solution at 412 nm. TChE hydrolyzes ACh, generating acetic acid and choline, which can react with a thiol chromogenic agent to form the yellow compound 1,3,5-trinitrobenzene at 412 nm. The protein content in the brain was quantified using the Coomassie brilliant blue assay.

**Histology and immunohistochemistry**

Six mice per group, mice that were not used for the brain biochemistry assays, were transcardially perfused with 25 ml of ice-cold saline containing 30IU heparin sodium followed by 50
ml of 4% paraformaldehyde in 0.01 M phosphate-buffered saline (pH 7.2–7.4). Their brains were removed and post-fixed in the same solution overnight, and then, they were embedded in paraffin and sectioned at a thickness of 4 μm. The resulting sections were placed overnight in an oven at 68°C, then deparaffinized in three changes of xylol, rehydrated in a graded series of alcohol, and washed with distilled water. They were then immersed in fresh 3% H2O2 to inactivate endogenous peroxidase and were again washed with distilled water. For antigen retrieval, the sections were placed in 10 mmol citrate buffer (pH 6.0) for 4 min at 2100°C in a pressure cooker. Afterwards, they were cooled to room temperature over 40 min and then blocked in 5% bovine serum albumin and incubated with a primary antibody against Aβ1−42 overnight at 4°C. The sections were incubated with biotinylated anti-mouse IgG secondary antibody for 20 min and then with a diaminobenzidine (DAB) solution using the Vector DAB peroxidase substrate kit (Vector Laboratories, Burlingame, CA, USA), followed by counterstaining with methylene blue for 20 s. After clearing in xylene, the sections were cover-slipped for examination under a light microscope. Some sections were stained with hematoxylin and eosin (H & E) for histopathological examination [37].

Data analysis
Statistical analyses were performed with SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA). Data corresponding to biochemical parameters were presented as mean ± standard error of the mean and were analyzed with the unpaired student’s t test. The results from the Morris water maze and avoidance task were analyzed by analysis of variance (ANOVA) for repeated measures and the χ² test, respectively. P < 0.05 was considered statistically significant.

Results
Animal body weight and food intake
There was no significant difference in the daily food intake across groups (LG, 3.39 ± 0.18 g; HG, 3.34 ± 0.22 g; MG, 3.63 ± 0.26 g; NG, 3.51 ± 0.23 g), and over time, the body weights of all the mice (regardless of group affiliation) were similar up to 9 months of age (Fig 2).
Behavioral tests

The Morris water maze test took place over 5 days, and the mice were provided different entry points to the pool (Fig 3). The latency until the mice found the platform in each trial became shorter over this period, indicating that the mice were learning to navigate the maze (Fig 4A). At 3 months after the start of treatment, the NG and HG had shorter latencies than the MG (repeated measures ANOVA [38]; P < 0.001), but the same was not true for the LG (P = 0.310). Likewise, at 7 months, only the NG and HG (P < 0.001), but not the LG (P = 0.972), performed better on the test than the MG. There was no statistical difference in the latency between the NG and HG (at 3 months, P = 0.596; at 7 months, P = 0.972), while the LG did not differ from the MG (at 3 month, P = 0.106 and at 7 months, P = 0.203) (Fig 4B).

In the shutter box escape/avoidance test, the percentage of active or passive avoidances and escape failures during the 40-trial session was recorded (Table 2). Compared to the MG, there was a higher incidence of active avoidance and fewer escape failures in the NG, HG, and LG at 3 and 7 months, (P < 0.001 for all groups at both time points). The escape latency was also lower in the NG and HG than in the MG (unpaired student’s t test; at 3 and 7 months, P < 0.01 for both groups).

ACh and TChE levels in serum and brain

The ACh serum level was similar across all groups at 3 months (Table 3); however, at 7 months, a higher level was observed in the HG and LG compared to the MG (P < 0.05). Conversely, the serum TChE level was reduced in the HG, LG, and NG compared to the MG at both 3 and 7 months (P < 0.05).
In the brain, ACh was increased in only the HG at 3 months and in the HG, LG, and NG at 7 months (Table 3). In contrast, the TChE levels were lower in the HG, LG, and NG than in the MG at both 3 and 7 months.

Indicators of oxidative stress

The MDA level in the serum at 3 months was lower in both the LG (P < 0.05) and HG (P < 0.01) than in the MG (Table 4); moreover, the level in the HG was markedly lower than

Table 2. Results from the two-way (shuttle-box) active avoidance training.

|                  | LG*** | HG*** | MG    | NG*** |
|------------------|-------|-------|-------|-------|
| **Intervention for 3 months** |       |       |       |       |
| Active avoidances response(%) | 45.00 | 46.67 | 20.83 | 44.38 |
| Passive avoidances response(%) | 30.42 | 27.92 | 40.63 | 28.96 |
| Escape failures(%) | 24.58 | 25.41 | 38.54 | 26.66 |
| Escape latency(s) | 6.90±2.29* | 5.75±2.58* | 9.58±2.85 | 5.15±1.52* |
| **Intervention for 7 months** |       |       |       |       |
| Active avoidances response(%) | 30.63 | 45.00 | 29.38 | 42.29 |
| Passive avoidances response(%) | 53.33 | 25.63 | 21.46 | 32.92 |
| Escape failures(%) | 16.04 | 29.38 | 49.17 | 24.79 |
| Escape latency(s) | 7.60±2.57* | 7.33±2.05* | 10.58±3.00 | 6.92±1.67* |

Note: (1) LG-low intervention group, HG- high intervention group, MG- model group, NG- negative control group. (2) The percentage of active avoidances, passive avoidances, and escape failures ***P<0.001, compared with MG. (3) Escape latency(s): the average response latency for the 40-trials in the shuttle box training session; n = 12, * P<0.01.
Table 3. Distribution of Ach and TChE in serum and brains for the four groups (Mean ± SD, n = 6/12).

|          | LG     |         | HG     |         | MG     |         | NG     |         |
|----------|--------|---------|--------|---------|--------|---------|--------|---------|
|          | 3 m    | 7 m     | 3 m    | 7 m     | 3 m    | 7 m     | 3 m    | 7 m     |
| In Brain |        |         |        |         |        |         |        |         |
| Ach (μg/ml) | 56.43±12.03 | 56.80±17.10* | 74.81±9.45** | 53.11±12.59** | 50.74±11.65 | 35.08±3.44 | 70.50±10.01** | 58.28±8.96*** |
| TChE (U/ml) | 0.91±0.29 | 0.84±0.37 | 0.83±0.18* | 0.73±0.24* | 1.14±0.29 | 0.99±0.15 | 0.79±0.17* | 0.74±0.16* |

Note: (1) LG-low intervention group, HG- high intervention group, MG- model group, NG- negative control group. (2): *P<0.05, **P<0.01, ***P<0.001 compared with MG. (3) in brain, n = 6; in serum, n = 12.

doi:10.1371/journal.pone.0143135.t003

Table 4. Distribution of indicators of oxidative stress of brain and serum for the four groups (Mean ± SD, n = 6/12).

|          | LG     |         | HG     |         | MG     |         | NG     |         |
|----------|--------|---------|--------|---------|--------|---------|--------|---------|
|          | 3 m    | 7 m     | 3 m    | 7 m     | 3 m    | 7 m     | 3 m    | 7 m     |
| In Brain |        |         |        |         |        |         |        |         |
| Total Protein (g/l) | 0.40±1.13 | 0.47±0.22* | 0.36±0.06* | 0.41±0.05*** | 0.50±0.10 | 0.68±0.08 | 0.34±0.05** | 0.39±0.06*** |
| SOD (U/mg) | 3.09±0.39* | 2.41±0.36* | 3.18±0.64* | 2.72±0.42** | 2.25±0.76 | 1.94±0.33 | 3.08±0.76* | 2.47±0.43* |
| MDA (nmol/mg) | 2.30±0.66* | 2.82±0.92* | 2.23±0.95* | 2.83±0.89* | 3.73±1.15 | 4.62±1.65 | 2.06±0.85* | 2.74±0.72* |
| GSH-Px (U/mg) | 26.03±14.90 | 30.51±9.15* | 41.12±5.71*** | 31.45±1.39*** | 22.44±4.35 | 20.55±1.36 | 41.59±6.49*** | 31.10±2.03*** |

Note: (1) LG-low intervention group, HG- high intervention group, MG- model group, NG- negative control group. (2): *P<0.05, **P<0.01, ***P<0.001 compared with MG. (3) in brain, n = 6; in serum, n = 12.

doi:10.1371/journal.pone.0143135.t004

Pathologic changes in brains

At 9 months old, fewer neurons and pycnotic neuronal nuclei were observed in the cerebral cortex and hippocampus of the transgenic mice but not the wild-type by H & E staining (Fig 5A and 5B). Immunohistochemistry with an antibody against Aβ₁-42 (Fig 5C and 5D) revealed an increase in the number and volume of amyloid plaques proportional to the age of the mice (data not shown). Additionally, fewer plaques were observed in the cortex and hippocampus of in the LG (P < 0.05). In contrast, the SOD level was higher in the NG, HG, and LG compared to the MG at 3 months. Similar trends were also observed at 7 months.

The MDA, SOD, and GSH-Px levels in the brain tissue are shown in Table 4. Relative to the levels in the MG, the MDA level was lower in the NG, HG, and LG, whereas the SOD and GSH-Px levels were higher. Furthermore, the total protein content in the brain was lower in these three groups than in the MG at 7 months (P < 0.05).
the mice in the LG and HG after 7 months of treatment compared to the MG at the same age (Fig 5D), thus suggesting that early intervention with this nutrient combination can suppress the development of amyloid plaques.

Discussion

In this study, it was demonstrated that APP-PSN mice experience a significant improvement in cognitive function as well as in biochemical and histological indicators of AD after consuming a mixture of nutrients for up to 7 months.

Cognitive dysfunction is one of the major clinical manifestations of AD and is correlated with the loss of hippocampal and cortical synapses [39] that serve as the cellular substrates for spatial learning and memory [35]. In this study, the rate of memory decline was reduced along with the amelioration in cognitive function in mice after dietary intervention, thereby suggesting that this could be a possible strategy for delaying or preventing AD symptoms in humans [40].

During aging, oxidative stress resulting from reactive oxygen species (ROS) production increases even as endogenous antioxidant mechanisms progressively decay. These could be exacerbated in AD. In fact, a growing body of evidence implicates the early involvement of oxidative stress in the pathogenesis and progression of AD [41, 42]. The attack of lipids, proteins, sugars, and nucleic acids by free radicals leads to the formation of byproducts that can be detected in fluids and tissues and ultimately can serve as markers of oxidative damage [43]. Accordingly, lower levels of the oxidative stress indicators MDA, SOD, and GSH-PX were observed in the mice that were receiving the dietary supplement in this study, which could be due to the antioxidant micronutrients, such as selenium, lutein, zinc, and vitamin E.

Acetylcholinesterase and the cholinergic system, which are involved in learning and memory, may also play a role in AD. TChE belongs to a family of α/β hydrolases that catalyze the
hydrolysis of ACh at the cholinergic synapse [44]. Some studies have described a decrease in ACh and an increase in the TChE level in the brain as contributing factors to memory dysfunction in AD [45–47]. The present findings were consistent with these reports. The AD mice consuming the nutrient mixture had a higher ACh level than those who were fed regular chow, while the TChE level was reduced. Thus, increasing the ACh level in the brain by modulating TChE activity and signaling pathways mediated through cholinergic receptors that promote nonamyloidogenic APP processing and decrease tau phosphorylation are potential strategies for AD therapy [48]. Furthermore, the amyloid cascade hypothesis has been proposed to explain the pathogenesis of AD. The deposition of Aβ is the initial pathological event, which then triggers a cascade of events that include the formation of senile plaques, followed by neurofibrillary tangles, and this cascade ultimately results in neuronal death and dementia [49, 50]. Here, it was found that the Aβ deposition in the treatment groups was decreased compared to the AD model mice who were fed a regular diet. Thus, the protective effects of these nutrients may be direct—by promoting neural repair and inhibiting the formation of amyloid plaques—or else auxiliary, through antioxidative mechanisms or by lowering homocysteine.

Lastly, there are some limitations to this study. First, it is not clear that the beneficial effects of the tested nutrient combination would translate to humans. Moreover, not all of the components are commercially available. In the future, preclinical trials will be carried out to assess specific early biomarkers of AD using metabolomics approaches. In conclusion, the findings presented here suggest that a combination of nutrients may synergize to delay the symptoms of AD and that early intervention by dietary supplementation is a viable strategy for AD management.

Acknowledgments

The study was supported by a grant from the National Natural Science Foundation of China (no. 81273193). No conflicts of interest are declared.

Author Contributions

Conceived and designed the experiments: QHW YHW DCW. Performed the experiments: YC SYW CW YZ. Analyzed the data: SYW YC WX LM. Contributed reagents/materials/analysis tools: JFZ RD. Wrote the paper: SYW YC CW.

References

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007; 3: 186–191. doi: 10.1016/j.jalz.2007.04.381 PMID: 19595937
2. Goedert M, Spillantini M G. A century of Alzheimer’s disease. Sci. 2006; 314: 777–781.
3. McKeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol. 2005; 4: 735–742. PMID: 16239180
4. Butterfield D A, Swomley A M, Sultana R. Amyloid β-Peptide (1–42)-Induced Oxidative Stress in Alzheimer Disease: Importance in Disease Pathogenesis and Progression. Antioxid Redox Signal. 2013; 19: 823–835. doi: 10.1089/ars.2012.5027 PMID: 23249141
5. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J. Epigenetic mechanisms in Alzheimer’s disease. Neurobiol Aging. 2011; 32: 1161–1180. doi: 10.1016/j.neurobiolaging.2010.08.017 PMID: 21482442
6. Pimplikar S W, Nixon R A, Robakis N K, Shen J, Tsai LH. Amyloid-independent mechanisms in Alzheimer’s disease pathogenesis. J Neurosci. 2010; 30: 14946–14954. doi: 10.1523/JNEUROSCI.4305-10.2010 PMID: 21068297
7. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim Biophys Acta. 2010; 1802: 2–10. doi: 10.1016/j.bbadis.2009.10.006 PMID: 19853658
10. Ji HF, Shen L. Berberine: a potential multipotent natural product to combat Alzheimer's disease. Molecules. 2011; 16: 6732–6740. doi: 10.3390/molecules1606732 PMID: 21829148

11. Hofrichter J, Krohn M, Schumacher T, Lange C, Walbroel B, et al. Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABC1 and microglia activation in mice. Curr Alzheimer Res. 2013; 10: 1057–1069. PMID: 24156265

12. Colantuoni E, Surplus G, Hackman A, Arrighi HM, Brookmeyer R. Web-based application to project the burden of Alzheimer's disease. Alzheimers Dement. 2010; 6: 425–428. doi: 10.1016/j.jalz.2010.01.014 PMID: 20691645

13. Douaud G, Refsum H, de Jager CA, Reiserer RS, Harrison FE, Syverud DC, McDonald MP. Impaired spatial learning in the APPSwe+ΔE9 bigenic mouse model of Alzheimer’s disease. Genes Brain Behav. 2007; 6: 54–65. PMID: 17233641

14. Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, et al. Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial. J Alzheimers Dis. 2010; 6: 1–10.e1. doi: 10.1016/j.jalz.2009.10.003 PMID: 21697340

15. Nolan JM, Loskutova E, Howard A, Mulcahy R, Moran R, Stack J, et al. The impact of supplemental macular carotenoids in Alzheimer’s disease: a randomized clinical trial. J Alzheimers Dis. 2015; 44: 1157–1169. doi: 10.3233/JAD-142265 PMID: 25408222

16. Chew EY, Clemons TE, Agrón E, Launer LJ, Grodstein F, Bernstein PS, et al. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. JAMA. 2015; 314: 791–801. doi: 10.1001/jama.2015.9677 PMID: 26305649

17. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004; 13: 159–170. PMID: 14645205

18. Subash S, Essa MM, Al-Asmi A, Al-Adawi S, Vaishnav R, Guillenin GJ. Effect of dietary supplementation of dates in Alzheimer's disease APPsw/2576 transgenic mice on oxidative stress and antioxidant status. Nutr Neurosci. 2015; 18: 281–288. doi: 10.1179/1476830514Y.0000000134 PMID: 24954036

19. Subash S, Essa MM, Braidy N, Awlad-Thani K, Vaishnav R, Al-Adawi S, et al. Guillemin. Diet rich in date palm fruits improves memory, learning and reduces beta amyloid in transgenic mouse model of Alzheimer's disease. J Ayurveda Integr Med. 2015; 6: 116–120. doi: 10.4103/0975-9476.159073 PMID: 26167001

20. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993; 123: 1939–1951. PMID: 8229312
28. Garthe A, Kempeermann G. An old test for new neurons: refining the Morris water maze to study the functional relevance of adult hippocampal neurogenesis. Front Neurosci. 2013; 7: 63. doi: 10.3389/fnins.2013.00063 PMID: 23653589

29. Dong Z, Bai Y, Wu X, Li H, Gong B, Howland JG, et al. Hippocampal long-term depression mediates spatial reversal learning in the Morris water maze. Neuropharmacology, 2013; 64: 65–73. doi: 10.1016/j.neuropharm.2012.06.027 PMID: 22732443

30. Banerjee R, Ghosh AK, Ghosh B, Mondal AC, Banerjee R. Effect of chronic inescapable footshock and antidepressive treatment on BDNF/TrkB levels in rat hippocampus. Research and Reviews: A Journal of Neuroscience. 2012; 2: 12–21.

31. Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, et al. Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res. 2011; 1368: 239–247. doi: 10.1016/j.brainres.2010.10.053 PMID: 20971085

32. Qiu H, Jin GQ, Jin RF, Zhao WK. Analysis of variance of repeated data measured by water maze with SPSS. Journal of Chinese Integrative Medicine. 2007; 5: 101–105. PMID: 17214947

33. Mitew S, Kirkcaide MT, Dickson TC, Vickers JC. Altered synapses and gliotransmission in Alzheimer's disease and mild cognitive impairment. Ageing Res Rev. 2009; 8: 285–305. doi: 10.1016/j.arr.2009.04.002 PMID: 19376275

34. Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol. 2010; 69: 155–167. doi: 10.1097/EN.0b013e3181cb5a4f PMID: 20804018

35. Reddy VP, Zhu X, Perry G, Smith MA. Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis. 2009; 16: 763–774. doi: 10.3233/JAD-2009-1013 PMID: 19387111

36. Mangialasche F, Poldori MC, Monastero R, Ercolani S, Camarda C, Cecchetti R, et al. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res Rev. 2009; 8: 257–277. doi: 10.1016/j.arr.2009.04.002 PMID: 19376275

37. Kaladhar D, Anusha N, Rao VV, Surekha C, Meesala S. Regulation of Metabolic Syndromes by means of controlling diseased Ache and Bche with Multitarget Inhibitors through in silico techniques. Journal of Computational Methods in Molecular Design. 2012; 2: 122–129.

38. Naik RS, Hartmann J, Kiewert C, Duyens EG, Lockridge O, Klein J. Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009; 12: 79–85. PMID: 19470293

39. Golde TE, Petrucelli L, Lewis J. Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol. 2010; 223: 252–266. doi: 10.1016/j.expneurol.2009.07.035 PMID: 19716367

40. Darreh-Shori T, Soininen H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies. Curr Alzheimer Res. 2010; 7: 67–73. PMID: 20205672

41. Hu JJ, Li J, Wei Z, Gu HY, Shao BY, Long DW, et al. The PARF Antagonist AChE Inhibitor PM777 Attenuates LPS-Induced Acute Neuroinflammation. Neuroscience & Medicine. 2011; 2: 355–362.

42. Armstrong RA. The pathogenesis of Alzheimer's disease: a reevaluation of the "amyloid cascade hypothesis". Int J Alzheimers Dis. 2011; 2011: 630865. doi: 10.4061/2011/630865 PMID: 21331369

43. Lane RM, Kivipelto M, Greig N H. Acetylcholinesterase and its inhibition in Alzheimer disease. Clinical neuropharmacology. 2004; 27: 141–149. PMID: 15190239

44. Munoz-Torrero D. Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimers Disease. Current medicinal chemistry. 2008; 15: 2433–2455 PMID: 19855672

45. Jäger R, Purpura M, Kingsley M. Phospholipids and sports performance. Journal of the International Society of Sports Nutrition. 2007; 4: 5. PMID: 17908342

46. Parker AG, Gordon J, Thornton A, Byars A, Lubker J, Bartlett M, et al. The effects of IQPLUS Focus on cognitive function, mood and endocrine response before and following acute exercise. J Int Soc Sports Nutr. 2011; 8: 16. doi: 10.1186/1550-2783-8-16 PMID: 22017963

47. Bhalla V, Arora H, Dhir A, Kumar M. A triphenylene based zinc ensemble as an oxidation inhibitor. Chem. Commun. 2012; 48: 4722–4724.

48. Aliev G, Obrenovich ME, Reddy VP, Shenk JC, Moreira PI, Nunomura A, et al. Antioxidant therapy in Alzheimer disease and AD model mice. Neurobiol Aging. 2008; 29: 775–79. PMID: 17718520

49. Tassoni D, Kaur G, Weisinger RS, Sinclair AJ. The role of eicosanoids in the brain. Asia Pacific journal of clinical nutrition. 2007; 16: 228–235. PMID: 18296342

50. Clarke R. Lowering blood homocysteine with folic acid-based supplements: meta-analysis of randomised trials. Indian Heart J. 2000; 52: S59–64. PMID: 11339443